Actively Recruiting
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
Led by Suzhou BlueHorse Therapeutics Co., Ltd. · Updated on 2026-05-13
45
Participants Needed
5
Research Sites
148 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
After receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1, experimental group 2 and the control group in this Phase IIa clinical trial. The study will be followed up until 24 to 36 months after treatment.
CONDITIONS
Official Title
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years old at the time of informed consent
- Expected survival time longer than 3 months
- ECOG performance status of 0 or 1
- Pathologically diagnosed with resectable non-small cell lung cancer
- Received preoperative neoadjuvant therapy including PD-1 antibody
- Negative for driver gene mutations
- No disease recurrence after surgery
- Expected to complete standard adjuvant therapy
- Tumor lesions suitable for surgical resection or biopsy
- Sufficient blood and organ function
- Voluntarily signed informed consent form
You will not qualify if you...
- History of other malignant tumors within the past 5 years, except certain well-treated cancers
- Unresolved adverse reactions from previous treatments above grade 1 (with some exceptions)
- Previous severe immune-related adverse reactions (grade 4 or higher) from immunotherapy
- Received vaccination within 2 months before consent or plans to receive vaccination during study
- Received TIL, allogeneic T cell, or NK cell therapy within 6 months before consent
- Previous allogeneic stem cell or solid organ transplantation
- Active autoimmune disease or suspected autoimmune disease
- Significant pleural effusion or ascites requiring treatment
- Current or irreversible interstitial lung disease
- Serious cardiovascular or cerebrovascular diseases
- Active infection needing systemic treatment
- Infectious diseases such as hepatitis B, hepatitis C, syphilis, or AIDS
- Esophageal or gastric varices requiring intervention or high bleeding risk
- Uncontrolled metabolic or systemic diseases that increase medical risks
- Known allergy to study drug components
- Pregnant or breastfeeding women
- Other severe medical, mental, or laboratory conditions increasing study risks or affecting results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Actively Recruiting
2
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Actively Recruiting
3
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Not Yet Recruiting
4
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Actively Recruiting
5
The Third People's Hospital of Chengdu
Chengdu, Sichuan, China
Not Yet Recruiting
Research Team
Y
Yilong Wu, Prof. Dr. Med
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here